Abstract
Use of <scp>S</scp>orafenib as an effective treatment in an <scp>AML</scp> patient carrying a new point mutation affecting the <scp>J</scp>uxtamembrane domain of <i><scp>FLT</scp>3</i>
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have